Diclofenac add-on to Treatment as Usual for Suicidal Patients
NCT ID: NCT01413854
Last Updated: 2019-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2011-08-31
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..
NCT01200524
To Check Dermatological Safety of Test Products by 24 Hours Patch Testing
NCT07060976
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
NCT00120120
Duloxetine for LBP
NCT05851976
Duloxetine for PHN
NCT04313335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
diclofenac
Diclofenac
50 mg, two times daily (oral adm.) during four weeks
sugar pill
sugar pill
One tablet two times daily during four weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sugar pill
One tablet two times daily during four weeks
Diclofenac
50 mg, two times daily (oral adm.) during four weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Montgomery Asberg Rating Scale Score more than 20 p.
* Recent suicide attempt (Treated as inpatient due to a recent suicide attempt)
* Informed consent
* Competence to give informed consent
Exclusion Criteria
* Breastfeeding
* Serious somatic disease e.g. serious heart, vascular, hepatic, kidney, pulmonary, intestinal, endocrine, haematological or neurological diseases
* Ongoing substance abuse
* Schizophrenia or other psychotic disorders
* Ongoing psychosis
* Risk factors for cardiovascular events
* Ulcer or gastrointestinal bleeding
* Ongoing Electroconvulsive therapy
* Previous allergic reaction to NSAID, acetylsalicylic acid, sulfonamides or the diclofenac or sugar pill content
* Galactose intolerance, lactase deficiency or glucose-galactose malabsorption
* Ongoing treatment with warfarin or other anticoagulants
* Ongoing treatment with ACE inhibitors or angiotensin II antagonists Ongoing treatment with drugs known to effect the immune system Ongoing treatment with rifampicin, carbamazepine or barbiturates
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Skane
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Åsa Westrin, MD, Phd
Role: PRINCIPAL_INVESTIGATOR
Lund University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Psychiatry Skane
Lund, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
eudraCT number 2010-021024-10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.